The Benefits of TZDs for Early Type 2 Diabetes
The Benefits of TZDs for Early Type 2 Diabetes
Oral Agents for Diabetes: What to Choose and When
Oral Agents for Diabetes: What to Choose and When
Report From Capitol Hill with AMA Board Chair Dr. Rebecca Patchin
Report From Capitol Hill with AMA Board Chair Dr. Rebecca Patchin
The Battle Continues Against Pharmacological Cheating in Sports
The Battle Continues Against Pharmacological Cheating in Sports
Multiple Choice: Customizing Insulin Therapy
Multiple Choice: Customizing Insulin Therapy
As Prescribed: Meeting the Challenges of Medication Adherence
As Prescribed: Meeting the Challenges of Medication Adherence
In-Office Drug Testing for Retinal Conditions
In-Office Drug Testing for Retinal Conditions
The Potential of Immunotherapy in Type 1 Diabetes
The Potential of Immunotherapy in Type 1 Diabetes
Interventions Targeting Impaired Glucose Tolerance
Interventions Targeting Impaired Glucose Tolerance
The ARBITER 6-HALTS Trial: Clinical Implications
The ARBITER 6-HALTS Trial: Clinical Implications
Are Out-of-State Provider Licensing Laws Due for a Change?
Are Out-of-State Provider Licensing Laws Due for a Change?
How Will Pharmacogenomics Play a Role in Diabetes Therapy?
How Will Pharmacogenomics Play a Role in Diabetes Therapy?